|
|
News Breaks | | | | February 5, 2013 | | 07:06 EDT |  | VSTM | Verastem initiates Phase 1/1b trial of VS-6063
Verastem announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer. VS-6063 is a potent inhibitor of focal adhesion kinase and has demonstrated signs of clinical activity in ovarian cancer in a single agent, Phase 1 clinical trial. | |
|
News For VSTM From The Last 14 Days Check below for free stories on VSTM the last two weeks. |
|
|
| May 14, 2013 | | 07:04 EDT | | VSTM | Verastem appoints Jack Green as CFO
 Subscribe for More Information | | | May 9, 2013 | | 07:35 EDT |  | VSTM | Verastem reports Q1 EPS (44c), consensus (43c)
| |
|
|
|
|
|
|
